Generic Name and Formulations:
Methylphenidate 10mg, 15mg, 20mg, 30mg; delivered over 9hrs; transdermal patches.
Indications for DAYTRANA:
Attention deficit hyperactivity disorder.
<6yrs: not established. 6–17yrs: Initially apply one 10mg patch to hip 2hrs before desired effect, remove 9hrs after application; may remove earlier if shorter duration of effect or late day side effects appear. May titrate dose at 1-week intervals. Reevaluate periodically. Rotate application sites.
Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family. During or within 14 days of MAOIs.
History of drug dependence or alcoholism; monitor for abnormal behavior. Discontinue if contact sensitization is suspected; may develop systemic sensitization with other MPH formulations (see full labeling). Avoid exposing patch to direct external heat sources. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. History of vitiligo. Monitor for signs of skin depigmentation; discontinue if chemical leukoderma develops. Monitor growth, BP, HR, CBCs, differential, platelet counts. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), tricyclics (eg, imipramine, clomipramine, desipramine), SSRIs. May decrease effectiveness of antihypertensive agents. Caution with pressor agents. Risk of serotonin syndrome with serotonergic drugs.
Application site reactions (eg, erythema), decreased appetite, insomnia, nausea, vomiting, weight loss, tics, affect lability, anorexia, dizziness, abdominal pain, headache, irritability; priapism, hypertension, tachycardia, visual disturbances.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma